Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin
- 30 May 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Drug Research
- Vol. 72 (06) , 312-318
Abstract
Chemotherapy, which is one of the common treatments for osteosarcoma (OS), has many side effects and in some cases has low effectiveness due to chemoresistance, hence it is vital to study new therapies for OS. In this regard, we combined melatonin with cisplatin and evaluate their effect on MG63 OS cells. Since melatonin has anti-cancer properties, we hypothesized that its combination with cisplatin could increase the effectiveness of cisplatin. Firstly, MTT assay was used to evaluate the cell viability and cytotoxicity of cisplatin on MG63 cells and the results showed that melatonin in combination with cisplatin increases the sensitivity of MG63 cells to cisplatin. In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Furthermore, analysis of Annexin V/FITC assay data revealed that the rate of apoptosis in MG63 OS cell line remarkably promoted after treated with cisplatin and melatonin combination. As a result, our findings show that melatonin in combination with cisplatin increases the effectiveness of cisplatin in osteosarcoma cells and this study provides a new therapeutic approach for OS.Keywords
Funding Information
- Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences (64876)
This publication has 39 references indexed in Scilit:
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Clinical significance of CYLD downregulation in breast cancerBreast Cancer Research and Treatment, 2014
- Melatonin attenuates cisplatin-induced HepG2 cell deathviathe regulation of mTOR and ERCC1 expressionsWorld Journal of Hepatology, 2014
- miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review)Biomedical Reports, 2013
- Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal modelsEuropean Archives of Oto-Rhino-Laryngology, 2012
- Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulationOncogene, 2011
- Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 ProteinGenes & Cancer, 2010
- Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencingBiochemical and Biophysical Research Communications, 2009
- Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidationCarcinogenesis, 2009
- Livin and Bcl-2 expression in high-grade osteosarcomaJournal of Cancer Research and Clinical Oncology, 2007